The Claim
Sodium-glucose co-transporter-2 inhibitors (SGLT2is) are associated with a mean loss of 1.04 kg of lean body mass in adults with obesity or type 2 diabetes undergoing weight loss, with this loss accounting for approximately 21% of total weight reduction.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with obesity or type 2 diabetes who are losing weight, SGLT2 inhibitors are linked to an average loss of 1.04 kilograms of lean body mass, which makes up about 21% of the total weight lost.
See the scientific wording
Sodium-glucose co-transporter-2 inhibitors (SGLT2is) are associated with a mean loss of 1.04 kg of lean body mass in adults with obesity or type 2 diabetes undergoing weight loss, with this loss accounting for approximately 21% of total weight reduction, indicating a consistent but smaller proportional lean mass depletion compared to GLP-1RAs.
When the kidneys cannot reabsorb glucose due to SGLT2 inhibition, excess sugar is lost in urine. This creates a calorie deficit that forces the body to make new glucose from amino acids, which are pulled from muscle tissue. As a result, muscle mass decreases as protein is broken down to fuel glucose production.
What the research says
1 studyThis study found that SGLT2i weight loss drugs cause people to lose about 1 kg of muscle and lean tissue, which is roughly one-fifth of all the weight they lose — just like the claim says. It also shows GLP-1RA drugs cause more muscle loss, which matches the claim’s comparison.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.